Multifocal White Matter Lesions Associated with the D313Y Mutation of the α-Galactosidase A Gene

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lenders, Malte ^a   Duning, Thomas ^a   Schelleckes, Michael ^a   Schmitz, Boris ^a   Stander, Sonja ^a   Rolfs, Arndt ^b   Brand, Stefan Martin ^a   Brand, Eva ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; MESSENGER RNA;

ADULT; AGED; ALPHA GALACTOSIDASE A GENE; ARTICLE; BIOCHEMICAL COMPOSITION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE EXPRESSION; HUMAN; MALE; MISSENSE MUTATION; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIGREE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; WHITE MATTER LESION;

ALPHA-GALACTOSIDASE; FEMALE; HUMANS; LEUKOENCEPHALOPATHIES; MALE; MUTATION;

EID: 84873503578     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055565     Document Type: Article

References (32)

1. The LADIS Study Group, Poggesi A, Pantoni L, Inzitari D, Fazekas F, et al (2011) 2001-2011: A decade of the LADIS (Leukoaraiosis and disability) study: What have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis 32: 577-588.
2. Basile AM, Pantoni L, Pracucci G, Asplund K, Chabriat H, et al. (2006) Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis 21: 315-322.
3. Ringelstein EB, Kleffner I, Dittrich R, Kuhlenbaeumer G, Ritter MA, (2010) Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci 299: 81-85.
4. Zarate YA, Hopkins RJ, (2008) Fabry's disease. Lancet 372: 1427-1435.
5. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, et al. (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychatry 79: 1249-1254.
6. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, et al. (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2: 450-456.
7. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ, (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53: 1186-1197.
8. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, et al. (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Eng J Med 333: 288-293.
9. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, et al. (2003) Fabry Disease: Characterization of α-Galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Human Mutation 22: 486-492.
10. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I, (2003) Fabry disease: D313Y is an alpha-Galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80: 307-314.
11. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, et al. (1973) Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Lab Clin Med 81: 157-171.
12. Sachdev P, Chen X, Wen W, (2008) White matter hyperintensities in mid-adult life. Curr Opin Psychiatry 21: 268-274.
13. De Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, et al. (2000a) Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47: 145-151.
14. Enzinger C, Fazekas F, Ropele S, Schmidt R, (2007) Progression of cerebral white matter lesions- Clinical and radiological considerations. J Neurol Sci 257: 5-10.
15. Maxwell H, Hanby M, Parkes LM, Gibson LM, Cottinho C, et al. (2012) Prevalence and subtypes of radiological cerebrovascular disease in late-onset isolated seizures and epilepsy. Clin Neurol Neurosurg in press. Clinical Neurology and Neurosurgery webside. Available: http://www.clineu-journal.com/article/S0303-8467(12)00367-8. Accessed 2012 Jul 30.
16. De Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, et al. (2000b) Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychatry 57: 1071-1076.
17. Assareh A, Mather KA, Schofield PR, Kwok JB, Sachdev PS, (2011) The genetics of white matter lesions. CNS Neurosci Ther 17: 525-540.
18. Schiffmann R, van der Knaap MS, (2009) Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 72: 750-759.
19. Sims K, Politei J, Banikazemi M, Lee P, (2009) Stroke in Fabry disease frequently occurs before diagnosis and in absence of other clinical events: Natural history data from the Fabry Registry. Stroke 40: 788-794.
20. Froissart R, Piraud M, Maire I, (2010) Contribution of genotyping in Fabry's disease. Rev Med Interne 31: 275-278.
21. Tolouian R, Salameh H, (2010) Treat the patient not the lab value. NDTPlus 3: 81-83.
22. Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, et al. (2007) Prevalence of Fabry Disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. JACC 50: 2399-2403.
23. Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, et al. (2010) Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Medical Genetics 11: 19.
24. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, et al. (2010) Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 41: 78-81.
25. Baptista MV, Ferreira S, Pinho-e-Melo T, Carvalho M, Cruz VT, et al. (2010) Mutations of the GLA gene in young patients with stroke: The PORTYSTROKE study-Screening genetic conditions in Portuguese young stroke patients. Stroke 41: 431-436.
26. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, et al. (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40.
27. Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H, (2005) Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Am J Hum Genet 117: 317-328.
28. Sugarawa K, Ohno K, Saito S, Sakuraba H, (2008) Structurak characterization of mutant alpha-galactosidases causing Fabry disease. Am J Hum Genet 53: 812-824.
29. Tetaud C, Falguieres T, Carlier K, Lecluse Y, Garibal J, et al. (2003) Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and Verotoxin-1. JBC 278: 45200-45208.
30. Hoffmann B (2006) Effects of enzyme replacement therapy on pain and overall quality of life. In: Mehta A, Beck M, Sunder-PlassmannG, editors. Fabry Disease: Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; Chapter 40. Available: http://www.ncbi.nlm.nih.gov/books/NBK11580/.
31. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, et al. (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy- aretrospective analysis from the Fabry Outcome Survey. Clin J Pain 23: 535-542.
32. Mehta A, Beck M, Elliot P, Giugliani R, Linhart A, et al. (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374: 1986-1996.